Gorman Rupp Co (GRC) Holder Renaissance Technologies Has Lifted Its Holding; Eventide Asset Management Decreased Its Spark Therapeutics (ONCE) Position as Market Value Rose

August 12, 2018 - By Victoria Pittman

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Renaissance Technologies Llc increased its stake in Gorman Rupp Co (GRC) by 111.44% based on its latest 2018Q1 regulatory filing with the SEC. Renaissance Technologies Llc bought 31,315 shares as the company’s stock rose 23.96% while stock markets declined. The hedge fund held 59,415 shares of the fluid controls company at the end of 2018Q1, valued at $1.74 million, up from 28,100 at the end of the previous reported quarter. Renaissance Technologies Llc who had been investing in Gorman Rupp Co for a number of months, seems to be bullish on the $966.33 million market cap company. The stock decreased 0.83% or $0.31 during the last trading session, reaching $37. About 24,192 shares traded. The Gorman-Rupp Company (NYSEMKT:GRC) has risen 40.72% since August 12, 2017 and is uptrending. It has outperformed by 28.15% the S&P500. Some Historical GRC News: 25/04/2018 – GRC International Sees FY 2018 Results Ahead of Expectations; 13/03/2018 – Richland Source: Gorman-Rupp announces corporate staff promotions; 26/04/2018 – GORMAN-RUPP CO GRC.N – COMPANY’S BACKLOG OF ORDERS WAS $127.3 MLN AT MARCH 31, 2018 COMPARED TO $96.9 MLN AT MARCH 31, 2017; 01/05/2018 – Detailed Research: Economic Perspectives on NeoGenomics, Illinois Tool Works, Carriage Services, Gorman-Rupp, Fiesta Restaurant; 20/03/2018 – New Research Coverage Highlights Home, Gorman-Rupp, Aratana Therapeutics, Washington Real Estate Investment Trust, XG Technolog; 10/04/2018 – Lockpath Receives GRC Innovation Awards for Enterprise GRC and IT GRC Management; 06/03/2018 Gorman-Rupp Closes Above 200-Day Moving Average: Technicals; 02/05/2018 – TCS Wins GRC 20/20 Innovation and User Experience Awards; 27/04/2018 – Richland Source: Gorman-Rupp declares first quarter cash dividend; 27/04/2018 – Gorman-Rupp Company Declares Cash Dividend

Eventide Asset Management Llc decreased its stake in Spark Therapeutics Inc (ONCE) by 16.67% based on its latest 2018Q1 regulatory filing with the SEC. Eventide Asset Management Llc sold 54,000 shares as the company’s stock rose 31.00% while stock markets declined. The institutional investor held 270,000 shares of the health care company at the end of 2018Q1, valued at $17.98M, down from 324,000 at the end of the previous reported quarter. Eventide Asset Management Llc who had been investing in Spark Therapeutics Inc for a number of months, seems to be less bullish one the $2.19 billion market cap company. The stock increased 0.93% or $0.54 during the last trading session, reaching $58.42. About 605,909 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 41.78% since August 12, 2017 and is uptrending. It has outperformed by 29.21% the S&P500. Some Historical ONCE News: 10/04/2018 – AveXis sells on Novartis approach; 08/05/2018 – SPARK THERAPEUTICS 1Q LOSS/SHR $1.25, EST. LOSS/SHR 32C; 10/04/2018 – MOODY’S: $8.7 BILLION ACQUISITION OF AVEXIS STRENGTHENS NOVARTIS’S PIPELINE IN GENE THERAPY, BUT REDUCES FINANCIAL FLEXIBILITY; 08/05/2018 – SPARK THERAPEUTICS INC – $587.5 MLN IN CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018; 09/03/2018 – CHILDREN’S HOSPITAL OF PHILADELPHIA FOUNDATION – TO CONSIDER VIEW OF ISS, AMONG OTHERS REGARDING ELECTION OF SPARK THERAPEUTICS’ BOARD AT 2018 MEETING; 11/05/2018 – Spark Therapeutics Forms Golden Cross: Technicals; 30/04/2018 – ONCE TO SELL RARE PEDIATRIC DISEASE PRV FOR $110M; 01/05/2018 – Detailed Research: Economic Perspectives on Vitamin Shoppe, Surmodics, Spark Therapeutics, QUANTENNA COMMS, Westinghouse Air Br; 09/03/2018 – THE CHILDREN’S HOSPITAL OF PHILADELPHIA FOUNDATION REPORTS 10.7 PCT STAKE IN SPARK THERAPEUTICS AS OF MARCH 9, 2018 – SEC FILING; 30/04/2018 – Spark Therapeutics Sells Priority Review Voucher for $110 Million

Among 27 analysts covering Spark Therapeutics (NASDAQ:ONCE), 12 have Buy rating, 3 Sell and 12 Hold. Therefore 44% are positive. Spark Therapeutics had 88 analyst reports since August 21, 2015 according to SRatingsIntel. As per Thursday, July 20, the company rating was maintained by Chardan Capital Markets. BMO Capital Markets maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Wednesday, February 21. BMO Capital Markets has “Outperform” rating and $64 target. The company was maintained on Monday, April 30 by Cantor Fitzgerald. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Outperform” rating given on Thursday, March 8 by Credit Suisse. Stifel Nicolaus maintained the shares of ONCE in report on Wednesday, May 9 with “Buy” rating. The firm has “Hold” rating given on Tuesday, December 12 by UBS. The rating was maintained by Stifel Nicolaus on Wednesday, February 21 with “Buy”. As per Monday, October 5, the company rating was maintained by Roth Capital. The rating was maintained by Jefferies with “Buy” on Monday, September 4. The company was downgraded on Wednesday, September 2 by Zacks.

Eventide Asset Management Llc, which manages about $1.15B and $2.14B US Long portfolio, upped its stake in Zogenix Inc by 97,000 shares to 265,000 shares, valued at $10.61M in 2018Q1, according to the filing. It also increased its holding in Ventas Inc (NYSE:VTR) by 9,600 shares in the quarter, for a total of 19,500 shares, and has risen its stake in Atlantica Yield Plc.

Investors sentiment decreased to 1.19 in 2018 Q1. Its down 0.24, from 1.43 in 2017Q4. It turned negative, as 21 investors sold ONCE shares while 42 reduced holdings. 33 funds opened positions while 42 raised stakes. 36.74 million shares or 2.75% more from 35.76 million shares in 2017Q4 were reported. State Of Wisconsin Invest Board owns 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 26,500 shares. Jpmorgan Chase And has invested 0.03% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Natixis accumulated 14,320 shares or 0.01% of the stock. Pictet Asset Mngmt reported 0.04% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Fund Sa has 14,227 shares for 0.01% of their portfolio. Nomura Asset Mgmt Ltd accumulated 7,000 shares or 0.01% of the stock. Pinnacle Associate accumulated 234,430 shares. Tekla Cap Management Ltd Com accumulated 22,046 shares. Ubs Asset Mngmt Americas owns 144,940 shares. Credit Suisse Ag holds 0.01% or 148,446 shares in its portfolio. 1.50 million were reported by Federated Investors Inc Pa. Bailard has invested 0.32% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Susquehanna Group Llp reported 29,421 shares. Victory Management holds 0% or 394 shares. Daiwa Securities Grp Inc stated it has 204 shares or 0% of all its holdings.

More important recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Seekingalpha.com which released: “Spark Therapeutics 2018 Q2 – Results – Earnings Call Slides” on August 07, 2018, also Seekingalpha.com published article titled: “Rounds Report: Spark Therapeutics Ironically Topped Our Featured List Despite Its Depreciation”, Streetinsider.com published: “Pre-Open Movers 08/07: (VCEL) (MNK) (TWLO) Higher; (ONCE) (GEMP) (ZG) Lower (more…)” on August 07, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) was released by: Nasdaq.com and their article: “Mid-Day Market Update: Mallinckrodt Climbs After Q2 Beat; Gemphire Therapeutics Shares Plummet” with publication date: August 07, 2018.

Renaissance Technologies Llc, which manages about $63.99 billion and $91.44 billion US Long portfolio, decreased its stake in Square Inc by 598,977 shares to 173,723 shares, valued at $8.55M in 2018Q1, according to the filing. It also reduced its holding in Universal Ins Hldgs Inc (NYSE:UVE) by 44,100 shares in the quarter, leaving it with 24,200 shares, and cut its stake in Bwx Technologies Inc.

Since February 27, 2018, it had 0 insider buys, and 3 selling transactions for $248,237 activity. LAKE CHRISTOPHER H sold 1,500 shares worth $49,860.

The Gorman-Rupp Company (NYSE:GRC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts